Benitec Biopharma Inc. (NASDAQ:BNTC) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC lifted its position in Benitec Biopharma Inc. (NASDAQ:BNTC) by 134.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 197,096 shares of the biotechnology company’s stock after purchasing an additional 113,109 shares during the quarter. Geode Capital Management LLC owned approximately 0.85% of Benitec Biopharma worth $2,490,000 at the end of the most recent quarter.

Separately, Franklin Resources Inc. lifted its holdings in shares of Benitec Biopharma by 269.0% during the fourth quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company’s stock worth $37,123,000 after purchasing an additional 2,142,643 shares during the period. 52.19% of the stock is currently owned by hedge funds and other institutional investors.

Benitec Biopharma Trading Up 0.4 %

NASDAQ:BNTC opened at $13.64 on Tuesday. The firm has a market cap of $319.87 million, a price-to-earnings ratio of -9.03 and a beta of 0.76. The company’s 50-day moving average is $13.15 and its two-hundred day moving average is $11.73. Benitec Biopharma Inc. has a 12-month low of $5.74 and a 12-month high of $16.90.

Benitec Biopharma (NASDAQ:BNTC) last released its earnings results on Friday, February 14th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.19. On average, equities research analysts forecast that Benitec Biopharma Inc. will post -1.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $28.00 price objective on shares of Benitec Biopharma in a research note on Monday, March 24th. JMP Securities boosted their price objective on shares of Benitec Biopharma from $18.00 to $20.00 and gave the company a “market outperform” rating in a research note on Thursday, April 10th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Benitec Biopharma has a consensus rating of “Buy” and an average price target of $24.71.

Insiders Place Their Bets

In other Benitec Biopharma news, Director Suvretta Capital Management, L acquired 900,000 shares of the stock in a transaction that occurred on Wednesday, March 26th. The stock was acquired at an average price of $13.00 per share, with a total value of $11,700,000.00. Following the transaction, the director now directly owns 8,793,245 shares in the company, valued at approximately $114,312,185. This represents a 11.40 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.30% of the stock is currently owned by company insiders.

Benitec Biopharma Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.